22157.jpg
Cirrhosis Market and Pipeline Insights, 2024: Analysis of Emerging Drugs GXHPC 1 (GWOXI Stem Cell Applied Technology), LPCN 1148 (Lipocine), and Belapectin (Galectin Therapeutics)
11 avr. 2024 11h06 HE | Research and Markets
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Cirrhosis - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights...
Ocera Therapeutics R
Ocera Therapeutics Reports Second Quarter 2017 Financial Results
01 août 2017 16h05 HE | Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on the development...
Ocera Initiates Phas
Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis
01 juin 2017 09h05 HE | Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., June 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced the dosing of the first patients in Part Two of a...
Ocera Therapeutics H
Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
05 oct. 2015 16h05 HE | Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera Reports Pipeli
Ocera Reports Pipeline Progress and First Quarter 2015 Financial Results
30 avr. 2015 08h05 HE | Ocera Therapeutics, Inc.
Strong Enrollment in STOP-HE Trial Conference Call and Webcast at 10:00 a.m. ET PALO ALTO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage...
Ocera Therapeutics t
Ocera Therapeutics to Report Pipeline Progress and First Quarter 2015 Financial Results
22 avr. 2015 16h43 HE | Ocera Therapeutics, Inc.
PALO ALTO, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Reports Fourth
Ocera Reports Fourth Quarter and Full Year 2014 Financial Results
11 mars 2015 16h01 HE | Ocera Therapeutics, Inc.
PALO ALTO, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Therapeutics t
Ocera Therapeutics to Present at 13th Annual BIO Investor Forum
29 sept. 2014 09h00 HE | Ocera Therapeutics, Inc.
PALO ALTO, Calif., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Therapeutics R
Ocera Therapeutics Raises $25.2 Million in Public Offering
10 juil. 2014 08h33 HE | Ocera Therapeutics, Inc.
PALO ALTO, Calif., July 10, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) ("Ocera") today announced that it has priced an underwritten public offering of 4,200,000 shares of its common...
Ocera Therapeutics A
Ocera Therapeutics Announces Proposed Public Offering of Common Stock
09 juil. 2014 16h01 HE | Ocera Therapeutics, Inc.
PALO ALTO, Calif., July 9, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) ("Ocera" or "the Company") today announced that it intends to offer and sell, subject to market and other...